Comparative assessment of angiotensin receptor blockers in different clinical settings

References

• DzauVJAntmanEMBlackHRThe cardiovascular disease continuum validated: clinical evidence of improved patient outcomes: part II: Clinical trial evidence (acute coronary syndromes through renal disease) and future directionsCirculation2006114252871289117179035
   PubMed Web of Science ®Google Scholar
• DzauVJAntmanEMBlackHRThe cardiovascular disease continuum validated: clinical evidence of improved patient outcomes: part I: Pathophysiology and clinical trial evidence (risk factors through stable coronary artery disease)Circulation2006114252850287017179034
   PubMed Web of Science ®Google Scholar
• HoKKPinskyJLKannelWBLevyDThe epidemiology of heart failure: the Framingham StudyJ Am Coll Cardiol1993224 Suppl A6A13A8509564
   PubMed Web of Science ®Google Scholar
• StaessenJAWangJGThijsLCardiovascular protection and blood pressure reduction: a meta-analysisLancet200135892901305131511684211
   PubMed Web of Science ®Google Scholar
• SchmiederREMechanisms for the clinical benefits of angiotensin II receptor blockersAm J Hypertens200518(5 Pt 1):72073015882557
   PubMed Web of Science ®Google Scholar
• CareyRMSiragyHMNewly recognized components of the renin–angiotensin system: potential roles in cardiovascular and renal regulationEndocr Rev200324326127112788798
   PubMed Web of Science ®Google Scholar
• NickenigGHarrisonDGThe AT(1)-type angiotensin receptor in oxidative stress and atherogenesis: part I: oxidative stress and atherogenesisCirculation2002105339339611804998
   PubMed Web of Science ®Google Scholar
• NickenigGHarrisonDGThe AT(1)-type angiotensin receptor in oxidative stress and atherogenesis: Part II: AT(1) receptor regulationCirculation2002105453053611815439
   PubMed Web of Science ®Google Scholar
• UngerTStoppelhaarMRationale for double renin–angiotensinaldosterone system blockadeAm J Cardiol20071003A25J31J
   PubMed Web of Science ®Google Scholar
• BiollazJBrunnerHRGavrasIWaeberBGavrasHAntihypertensive therapy with MK 421: angiotensin II – renin relationships to evaluate efficacy of converting enzyme blockadeJ Cardiovasc Pharmacol1982469669726185790
   PubMed Web of Science ®Google Scholar
• StruthersADAldosterone escape during ACE inhibitor therapy in chronic heart failureEur Heart J199516Suppl N1031068682054
   PubMedGoogle Scholar
• SiragyHMAngiotensin receptor blockers: how important is selectivity?Am J Hypertens200215111006101412441224
   PubMedGoogle Scholar
• LewingtonSClarkeRQizilbashNPetoRCollinsRAge-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studiesLancet200236093491903191312493255
   PubMed Web of Science ®Google Scholar
• TurnbullFEffects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trialsLancet200336293951527153514615107
   PubMed Web of Science ®Google Scholar
• ManciaGDe BackerGDominiczakAGuidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC)J Hypertens20072561105118717563527
   PubMed Web of Science ®Google Scholar
• LithellHHanssonLSkoogIThe Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trialJ Hypertens200321587588612714861
   PubMed Web of Science ®Google Scholar
• DahlofBDevereuxRBKjeldsenSECardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenololLancet20023599311995100311937178
   PubMed Web of Science ®Google Scholar
• JuliusSKjeldsenSEWeberMOutcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trialLancet200436394262022203115207952
   PubMed Web of Science ®Google Scholar
• MochizukiSDahlofBShimizuMValsartan in a Japanese population with hypertension and other cardiovascular disease (Jikei Heart Study): a randomised, open-label, blinded endpoint morbidity-mortality studyLancet200736995711431143917467513
   PubMed Web of Science ®Google Scholar
• YusufSTeoKKPogueJTelmisartan, ramipril, or both in patients at high risk for vascular eventsN Engl J Med2008358151547145918378520
   PubMed Web of Science ®Google Scholar
• Kassler-TaubKLittlejohnTElliottWRuddyTAdlerEComparative efficacy of two angiotensin II receptor antagonists, irbesartan and losartan in mild-to-moderate hypertension. Irbesartan/Losartan Study InvestigatorsAm J Hypertens199811(4 Pt 1):4454539607383
   PubMed Web of Science ®Google Scholar
• MallionJSicheJLacourciereYABPM comparison of the antihypertensive profiles of the selective angiotensin II receptor antagonists telmisartan and losartan in patients with mild-to-moderate hypertensionJ Hum Hypertens1999131065766410516734
   PubMed Web of Science ®Google Scholar
• AnderssonOKNeldamSThe antihypertensive effect and tolerability of candesartan cilexetil, a new generation angiotensin II antagonist, in comparison with losartanBlood Press19987153599551878
   PubMedGoogle Scholar
• HednerTOparilSRasmussenKA comparison of the angiotensin II antagonists valsartan and losartan in the treatment of essential hypertensionAm J Hypertens199912(4 Pt 1):41441710232502
   PubMed Web of Science ®Google Scholar
• FlatherMDYusufSKoberLLong-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients. ACE-Inhibitor Myocardial Infarction Collaborative GroupLancet200035592151575158110821360
   PubMed Web of Science ®Google Scholar
• DicksteinKKjekshusJEffects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Optimal Trial in Myocardial Infarction with Angiotensin II Antagonist LosartanLancet2002360933575276012241832
   PubMed Web of Science ®Google Scholar
• PfefferMAMcMurrayJJVelazquezEJValsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or bothN Engl J Med2003349201893190614610160
   PubMed Web of Science ®Google Scholar
• PittBSegalRMartinezFARandomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE)Lancet199734990547477529074572
   PubMed Web of Science ®Google Scholar
• PittBPoole-WilsonPASegalREffect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial – the Losartan Heart Failure Survival Study ELITE IILancet200035592151582158710821361
   PubMed Web of Science ®Google Scholar
• CohnJNTognoniGA randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failureN Engl J Med2001345231667167511759645
   PubMed Web of Science ®Google Scholar
• McMurrayJJOstergrenJSwedbergKEffects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trialLancet2003362938676777113678869
   PubMed Web of Science ®Google Scholar
• GrangerCBMcMurrayJJYusufSEffects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trialLancet2003362938677277613678870
   PubMed Web of Science ®Google Scholar
• YusufSPfefferMASwedbergKEffects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved TrialLancet2003362938677778113678871
   PubMed Web of Science ®Google Scholar
• MassieBMCarsonPEMcMurrayJJIrbesartan in patients with heart failure and preserved ejection fractionN Engl J Med2008359232456246719001508
   PubMed Web of Science ®Google Scholar
• LewisEJHunsickerLGBainRPRohdeRDThe effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study GroupN Engl J Med199332920145614628413456
   PubMed Web of Science ®Google Scholar
• RavidMSavinHJutrinIBentalTKatzBLishnerMLong-term stabilizing effect of angiotensin-converting enzyme inhibition on plasma creatinine and on proteinuria in normotensive type II diabetic patientsAnn Intern Med199311885775818452322
   PubMed Web of Science ®Google Scholar
• ParvingHHLehnertHBrochner-MortensenJGomisRAndersenSArnerPThe effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetesN Engl J Med20013451287087811565519
   PubMed Web of Science ®Google Scholar
• BrennerBMCooperMEde ZeeuwDEffects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathyN Engl J Med20013451286186911565518
   PubMed Web of Science ®Google Scholar
• LewisEJHunsickerLGClarkeWRRenoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetesN Engl J Med20013451285186011565517
   PubMed Web of Science ®Google Scholar